p2ca peptide has been researched along with Mast-Cell Sarcoma in 1 studies
*Mast-Cell Sarcoma: A unifocal malignant tumor that consists of atypical pathological MAST CELLS without systemic involvement. It causes local destructive growth in organs other than in skin or bone marrow. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gajewski, TF; O'Herrin, S; Rivas, FV | 1 |
1 other study(ies) available for p2ca peptide and Mast-Cell Sarcoma
| Article | Year |
|---|---|
CD28 is not required for c-Jun N-terminal kinase activation in T cells.
Topics: Animals; Antibodies, Monoclonal; Antigen Presentation; CD28 Antigens; CD3 Complex; DNA-Binding Proteins; Enzyme Activation; Enzyme Induction; Gene Expression Regulation; H-2 Antigens; Histocompatibility Antigen H-2D; Interferon-gamma; Interleukin-2; JNK Mitogen-Activated Protein Kinases; Lymphocyte Activation; Mast-Cell Sarcoma; Mice; Mice, Knockout; Mice, Transgenic; Mitogen-Activated Protein Kinases; Oligopeptides; Phosphorylation; Protein Processing, Post-Translational; Receptors, Antigen, T-Cell; Signal Transduction; T-Lymphocyte Subsets; Th1 Cells; Th2 Cells | 2001 |